123 related articles for article (PubMed ID: 37500143)
1. Positive Ascites Cytology, Postoperative Chemotherapy and Prognosis of Stage I Ovarian Clear Cell Carcinoma.
Kubo-Kaneda M; Kondo E; Okugawa T; Yamawaki T; Hirata T; Tsuji M; Nagao K; Kato M; Yoshimura K; Ikeda T
Anticancer Res; 2023 Aug; 43(8):3799-3805. PubMed ID: 37500143
[TBL] [Abstract][Full Text] [Related]
2. Impact of surgical staging in stage I clear cell adenocarcinoma of the ovary.
Suzuki K; Takakura S; Saito M; Morikawa A; Suzuki J; Takahashi K; Nagata C; Yanaihara N; Tanabe H; Okamoto A
Int J Gynecol Cancer; 2014 Sep; 24(7):1181-9. PubMed ID: 25010038
[TBL] [Abstract][Full Text] [Related]
3. The clinical value of surgeons' efforts of preventing intraoperative tumor rupture in stage I clear cell carcinoma of the ovary: A Korean multicenter study.
Suh DH; Park JY; Lee JY; Kim BG; Lim MC; Kim JW; Bae DS; Park SY; Nam JH; Kim K; No JH; Kim YB
Gynecol Oncol; 2015 Jun; 137(3):412-7. PubMed ID: 25868967
[TBL] [Abstract][Full Text] [Related]
4. Survival impact of capsule status in stage I ovarian mucinous carcinoma-A mulicentric retrospective study.
Kajiyama H; Suzuki S; Yoshikawa N; Kawai M; Nagasaka T; Kikkawa F
Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():131-136. PubMed ID: 30685661
[TBL] [Abstract][Full Text] [Related]
5. A large-scale multi-institutional study evaluating prognostic aspects of positive ascites cytology and effects of therapeutic interventions in epithelial ovarian cancer.
Yoshihara M; Emoto R; Kitami K; Iyoshi S; Uno K; Mogi K; Tano S; Yoshikawa N; Matsui S; Kajiyama H
Sci Rep; 2021 Jul; 11(1):15154. PubMed ID: 34312408
[TBL] [Abstract][Full Text] [Related]
6. Long-term oncologic outcome and its prognostic indicators in reproductive-age women with ovarian clear-cell carcinoma.
Kajiyama H; Suzuki S; Yoshikawa N; Niimi K; Kawai M; Shibata K; Kikkawa F
Arch Gynecol Obstet; 2019 Sep; 300(3):717-724. PubMed ID: 31165243
[TBL] [Abstract][Full Text] [Related]
7. A retrospective study for investigating the relationship between old and new staging systems with prognosis in ovarian cancer using gynecologic cancer registry of Japan Society of Obstetrics and Gynecology (JSOG): disparity between serous carcinoma and clear cell carcinoma.
Yamagami W; Nagase S; Takahashi F; Ino K; Hachisuga T; Mikami M; Enomoto T; Katabuchi H; Aoki D
J Gynecol Oncol; 2020 Jul; 31(4):e45. PubMed ID: 32026659
[TBL] [Abstract][Full Text] [Related]
8. Positive peritoneal cytology at interval surgery is a poor prognostic factor in patients with stage T3c advanced ovarian carcinoma: A retrospective study.
Nagasaka K; Kawana K; Tomio K; Tsuruga T; Mori-Uchino M; Miura S; Tanikawa M; Miyamoto Y; Ikeda Y; Sone K; Adachi K; Matsumoto Y; Arimoto T; Oda K; Osuga Y; Fujii T
J Obstet Gynaecol Res; 2015 May; 41(5):755-62. PubMed ID: 25421004
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: an analysis of fully staged patients.
Takada T; Iwase H; Iitsuka C; Nomura H; Sakamoto K; Omatsu K; Takeshima N; Takizawa K
Int J Gynecol Cancer; 2012 May; 22(4):573-8. PubMed ID: 22398705
[TBL] [Abstract][Full Text] [Related]
10. Ovarian clear cell carcinoma, outcomes by stage: the MSK experience.
Shu CA; Zhou Q; Jotwani AR; Iasonos A; Leitao MM; Konner JA; Aghajanian CA
Gynecol Oncol; 2015 Nov; 139(2):236-41. PubMed ID: 26404183
[TBL] [Abstract][Full Text] [Related]
11. Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study.
Takano M; Sugiyama T; Yaegashi N; Sagae S; Kuzuya K; Udagawa Y; Tsuda H; Suzuki M; Kigawa J; Goto T; Tsuda H; Moriya T; Kikuchi Y
Int J Gynecol Cancer; 2010 Dec; 20(9):1506-10. PubMed ID: 21119366
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemotherapy for stage i ovarian clear cell carcinoma: is it necessary for stage IA?
Mizuno M; Kajiyama H; Shibata K; Mizuno K; Yamamuro O; Kawai M; Nakanishi T; Nagasaka T; Kikkawa F
Int J Gynecol Cancer; 2012 Sep; 22(7):1143-9. PubMed ID: 22801028
[TBL] [Abstract][Full Text] [Related]
13. Recurrence-predicting prognostic factors for patients with early-stage epithelial ovarian cancer undergoing fertility-sparing surgery: a multi-institutional study.
Kajiyama H; Mizuno M; Shibata K; Yamamoto E; Kawai M; Nagasaka T; Kikkawa F
Eur J Obstet Gynecol Reprod Biol; 2014 Apr; 175():97-102. PubMed ID: 24507757
[TBL] [Abstract][Full Text] [Related]
14. Impact of incomplete surgery and adjuvant chemotherapy for the intraoperative rupture of capsulated stage I epithelial ovarian cancer: a multi-institutional study with an in-depth subgroup analysis.
Yoshihara M; Tamauchi S; Iyoshi S; Kitami K; Uno K; Mogi K; Kajiyama H
J Gynecol Oncol; 2021 Sep; 32(5):e66. PubMed ID: 34378361
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant Chemotherapy May Not Be Necessary for Women with Stage IC1 Epithelial Ovarian Cancer.
Deng DM; Liao QY; Yang J; Chen J; Chen G; Bai HL; Zhang B; Li KZ
Curr Med Sci; 2022 Feb; 42(1):192-200. PubMed ID: 34755262
[TBL] [Abstract][Full Text] [Related]
16. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
[TBL] [Abstract][Full Text] [Related]
17. Adult ovarian granulosa cell tumors: analysis of outcomes and risk factors for recurrence.
Plett H; Ricciardi E; Vacaru V; Ramspott JP; Colombo N; Sehouli J; du Bois A; Garbi A; Richter R; Ataseven B; Aletti G; Braicu E; Heitz F; Portuesi R; Muallem MZ; Dagres T; Parma G; Roser E; Traut A; Multinu F; Harter P
Int J Gynecol Cancer; 2023 May; 33(5):734-740. PubMed ID: 36759002
[TBL] [Abstract][Full Text] [Related]
18. An exploratory analysis about cycles of adjuvant chemotherapy and outcomes by substage for stage I ovarian clear cell carcinoma: a single institution retrospective study.
Wang T; Zeng J; Li N; Zhang R; Song Y; Wu L
Am J Cancer Res; 2020; 10(12):4561-4567. PubMed ID: 33415019
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
20. Long-term results and prognostic factors in patients with epithelial ovarian cancer.
Brun JL; Feyler A; Chêne G; Saurel J; Brun G; Hocké C
Gynecol Oncol; 2000 Jul; 78(1):21-7. PubMed ID: 10873404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
